UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of Earliest Event Reported): ~~November~~December 519, 2007

Encysive Pharmaceuticals Inc.
__________________________________________
(Exact name of registrant as specified in its charter)


Delaware	0-20117	13-3532643
_____________________ (State or other jurisdiction	_____________ (Commission	______________ (I.R.S. Employer
of incorporation)	File Number)	Identification No.)

4848 Loop Central Drive, Suite 700, Houston, Texas		77081
_________________________________ (Address of principal executive offices)		___________ (Zip Code)


Registrant’s telephone number, including area code:		713-796-8822

Not Applicable
______________________________________________
Former name or former address, if changed since last report

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

[  ]  Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
[  ]  Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
[  ]  Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
[  ]  Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Top of the Form

Item 83.01 ~~Other~~Notice ~~Events~~of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing.

~~On November 5, 2007,~~ Encysive Pharmaceuticals Inc. (the "Company") announced that ~~open~~on ~~label~~December ~~observational~~19, ~~data~~2007 ~~from~~it received a ~~Columbia~~delisting ~~University~~warning ~~suggests~~letter ~~that~~from ~~sitaxsentan~~the ~~(Thelin™),~~Nasdaq aStock ~~selective endothelin A receptor antagonist~~Market, ~~may~~notifying ~~improve~~it ~~symptoms~~that ~~associated~~the ~~with~~Company’s ~~Eisenmenger~~closing ~~syndrome~~price ~~(ES).~~per ~~The~~share ~~analyses~~for ~~were~~its ~~presented~~common onstock ~~November~~was 5,below ~~2007 at~~ the ~~American Heart Association (AHA) Scientific Sessions 2007 meeting in Orlando~~$1.A00 ~~retrospective~~minimum ~~chart~~bid ~~review~~price ~~was~~for ~~performed~~30 ~~on 14~~ consecutive EStrading ~~patients~~days. As ~~(10~~a ~~females~~result, 4the ~~males;~~Company ~~age~~no 27longer ±meets 11Nasdaq’s ~~years)~~continued ~~initiating~~listing ~~open~~criteria, ~~label~~and ~~sitaxsentan~~has ~~therapy~~180 ~~(100~~calendar mgdays, ~~tablets~~or ~~daily)~~until atJune ~~Columbia~~16, ~~University~~2008, ~~between~~to ~~2002~~regain ~~and 2006~~compliance. ~~Baseline~~During ~~data~~this ~~were compared to short~~180-day ~~and~~period, ~~long-term~~Encysive ~~follow-up~~shares ~~data~~will atcontinue 12to ~~weeks~~trade ~~and~~on atthe ~~approximately one year~~Nasdaq. ~~There~~To ~~was~~regain acompliance, ~~significant decrease in~~ the ~~pulmonary~~closing ~~vascular~~bid ~~resistance~~price ~~(PVR)~~of tothe ~~systemic~~Company's ~~vascular~~common ~~resistance~~stock ~~(SVR)~~must ~~ratio,~~remain ~~consistent~~at ~~with~~or ~~pulmonary~~above ~~selectivity in these patients~~$1. ~~The~~00 ~~improvements~~for ina ~~PVR~~minimum ~~index~~of ~~and~~10 ~~six-minute~~consecutive ~~walk~~business ~~distance~~days ~~were~~prior ~~not~~to ~~significant. During~~ the ~~one-year~~end ~~follow-up,~~of ~~these~~the ES180 ~~patients~~calendar ~~had~~day nocompliance ~~significant change in resting systemic arterial oxygen saturation~~period. ~~About~~The ~~Eisenmenger~~Company ~~SyndromeEisenmenger~~may ~~syndrome~~also isbe aeligible ~~progressive~~for ~~cardiovascular~~an ~~condition~~additional ~~that~~180 ~~can~~calendar ~~develop~~day incompliance ~~individuals~~period ~~who~~by ~~have~~transferring ~~un-repaired~~to ~~congenital~~the ~~heart~~Nasdaq ~~defects~~Capital Market. If ESthe isCompany ~~initially~~does ~~associated~~not ~~with~~regain ~~increased~~compliance ~~pulmonary~~by ~~blood~~the ~~pressure~~end ~~that,~~of if the ~~congenital~~compliance ~~heart~~period ~~defect~~(s)or isany ~~not~~extension ~~repaired,~~thereof) ~~results~~and inchooses ~~reversal~~not ~~of the shunt from left~~ to ~~right~~appeal toNasdaq’s ~~right~~decision to ~~left~~delist ~~with~~its ~~progressive~~common ~~pulmonary~~stock, ~~vascular~~the ~~disease~~Company's ~~and~~common ~~progressive~~stock ~~cyanosis. ES~~will isbe ~~linked~~delisted tofrom ~~multi-organ damage and premature death~~Nasdaq. ~~There is currently no cure for ES once it is established.~~

This ~~current~~Current ~~report~~Report on Form 8-K contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements are subject to certain risks, trends and uncertainties that could cause actual results to differ materially from those projected. Among those risks, trends and uncertainties are: ~~decisions by~~ the ~~U.S.~~likelihood ~~Food~~that ~~and Drug Administration regarding whether and when to approve~~ our ~~drug~~common ~~application~~stock ~~for~~trades ~~THELIN™~~in ~~(sitaxsentan~~an ~~sodium),~~acceptable ~~our~~range ~~ability~~ to ~~raise~~remain ~~capital~~listed toon ~~fund~~Nasdaq; ~~cash~~the ~~requirements~~possibility ~~for~~of ~~future~~being ~~operations,~~eligible ~~timelines~~ for ~~initiating~~additional ~~new~~time ~~trials~~to ~~and~~regain ~~completing~~compliance; ~~ongoing~~the ~~clinical~~impact ~~trials for sitaxsentan sodium (THELIN™), our estimates~~ of ~~the~~any ~~sufficiency~~delisting of our ~~existing~~common ~~capital resources~~stock, as well as more specific risks, trends and uncertainties facing ~~Encysive~~the Company such as those set forth in its reports on Forms 8-K, 10-Q and 10-K filed with the U.S. Securities and Exchange Commission. Given these risks, trends and uncertainties, any or all of these forward-looking statements may prove to be incorrect. Therefore you should not rely on any such forward-looking statements. Furthermore, ~~Encysive~~The Company undertakes no duty to update or revise these forward-looking statements. The Private Securities Litigation Reform Act of 1995 permits this discussion.

Top of the Form

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	Encysive Pharmaceuticals Inc.
November 5, 2007	By:	/s/ Paul S. Manierre
December 19, 2008	By:	/s/ Paul S. Manierre
		Name: Paul S. Manierre
		Title: Vice President, General Counsel and Secretary

Filing Compare · ENCYSIVE PHARMACEUTICALS INC